Dare Bioscience, Inc. current report, 26 January 2021

Dare Bioscience, Inc. - 8-K Summary

Business Context and Reporting Period

This Form 8-K, dated January 26, 2021, reports on executive compensation decisions made by the Board of Directors of Dare Bioscience, Inc., a clinical-stage biopharmaceutical company. The filing details the approval of 2020 performance bonuses and the establishment of 2021 base salary and bonus targets for named executive officers.

Key Financial Metrics

The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on executive compensation metrics:

  • 2020 Performance Bonus Weighting: The Board awarded a 90% aggregate weighting to performance objectives for all employees, including named executive officers.
  • CEO Bonus (Sabrina Martucci Johnson): $182,271 (calculated as 90% of a 55% target of her 2020 base salary).
  • CFO Bonus (Lisa Walters-Hoffert): $92,793 (calculated as 90% of a 35% target of her 2020 base salary).
  • CSO Bonus (John Fair): $92,793 (calculated as 90% of a 35% target of his 2020 base salary).

Material Changes and Management Commentary

The Board adjusted the 2020 bonus payout to 90% of the target despite the original objectives being set before the COVID-19 pandemic. Management cited the following factors for this decision:

  • Pandemic Impact: Objectives did not initially account for pandemic disruptions. The Board considered the extraordinary response of employees in advancing clinical studies (DARE-BV1 Phase 3, DARE-HRT1 Phase 1) and recalibrating other programs (Ovaprene, Sildenafil Cream) to maintain timelines.
  • Operational Adjustments: Management focused on non-clinical development activities that could be conducted efficiently during the pandemic while protecting employee health.
  • 2021 Compensation Adjustments: To remain competitive, 2021 base salaries for the CEO, CFO, and CSO were increased by 10%. Target bonus percentages for 2021 were raised to 70% for the CEO and 40% for the CFO and CSO.

Risks and Contingencies

The filing highlights the risk of pandemic-related disruptions to clinical trial execution and business development milestones. The Board exercised discretion to adjust bonus weightings to reflect performance reasonably within management's control amidst these external challenges.

Investor Verification Checklist

  • Verify the specific 2020 base salaries for the CEO, CFO, and CSO to confirm the calculated bonus amounts.
  • Review the 2020 Annual Report (10-K) for details on the seven specific performance objectives and their achievement status.
  • Monitor future filings for the impact of the 10% salary increase and higher bonus targets on the company's cash burn rate.
  • Check for updates on the clinical progress of DARE-BV1, DARE-HRT1, Ovaprene, and Sildenafil Cream to assess the validity of the performance assessment.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.